Companies / NYR

NYRADA INC.

ASX:NYRPharmaceuticals, Biotechnology & Life Sciences
247.1M shares on issueASX (delayed) · as of 28 July 2026$0.55price · delayed$133.4Mmarket cap · indicative
C
Dilution grade

Share count grew 36% in 24 months; 3 cash raises in 24 months; options/rights overhang 136% of shares

Cash runway9.0 quarters of funding
Share-count growth (24m)35.5%
Raise cadence (24m)3 cash raises
Options & rights overhang136.1% of shares
In-the-money supply7.3% of shares
Pending proposed issuesnone

NYRADA INC.'s ordinary share count grew 35.5% between June 2024 and June 2026, to 247M shares. The company raised capital three times in that period for total disclosed proceeds of A$19.9M, most recently a A$8.2M placement in July 2025. Options and rights on issue could convert into 336M new shares, equal to 136.1% of the current share count, of which 7% are in the money at the current share price; the nearest expiry is June 2027. At the March 2026 quarter the company reported A$8.0M in available cash, about 9.0 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
136.1%
Max option dilution
7.3%
ITM option dilution
2
Raises · last 12 months
9.0 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 247.1M per ASX (delayed) (28 July 2026).
217.5M228.4M239.2MDec 24Sept 25July 26Cash raise · 30 July 2025Cash raise · 30 July 2025

Cash runway

9.0 qtrs
More than four quarters of funding at the recent spend rate.
$8.0M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
30 June 20263H · cancellationNYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED245.5MAppendix 3H
29 June 20262A · quoted issueNYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED245.7MAppendix 2A
29 June 20262A · quoted issueNYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED246.9MAppendix 2A
16 June 20262A · quoted issueNYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED245.5MAppendix 2A
25 May 20262A · quoted issueNYR : CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED245.3MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 2 in the last 12 months

$8.3M
Placement
30 July 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

136.1%
Total overhang · of current shares
7.3%
In the money · at current price
336.2M
Potential new shares
June 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
11 June 2026James BonnarBuy7k—$3k3Y notice
11 June 2026James BonnarBuy4k—$2k3Y notice
10 June 2026James BonnarBuy6k—$3k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026$PQuarterly Activities Report and Appendix 4C
15 July 2026$PResponse to ASX Price Query
15 July 2026Change in substantial holding - M Azzi
5 July 2026PROTECT-MI Phase IIa Clinical Trial Update No 2
30 June 2026Notification of cessation of securities - NYR
29 June 2026Cleansing Statement
29 June 2026Application for quotation of securities - NYR
29 June 2026Cleansing Statement
29 June 2026Application for quotation of securities - NYR
16 June 2026Cleansing Statement
16 June 2026Application for quotation of securities - NYR
15 June 2026Change of Director's Interest Notice - JB
15 June 2026PROTECT-MI Phase IIa Clinical Trial Update
3 June 2026Investor Presentation
3 June 2026Nyrada Successfully Completes Cardioprotection Pilot Study
28 May 2026Nyrada Receives A$2.455M R&D Tax Incentive Rebate
25 May 2026Cleansing Statement
25 May 2026Application for quotation of securities - NYR
21 May 2026Upcoming Expiry of Unlisted Options
19 May 2026$PXolatryp Enhances Anthracycline Anti-Tumour Efficacy

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.